HU229065B1 - Pharmaceutical moxifloxacin compositions - Google Patents

Pharmaceutical moxifloxacin compositions Download PDF

Info

Publication number
HU229065B1
HU229065B1 HU0104762A HUP0104762A HU229065B1 HU 229065 B1 HU229065 B1 HU 229065B1 HU 0104762 A HU0104762 A HU 0104762A HU P0104762 A HUP0104762 A HU P0104762A HU 229065 B1 HU229065 B1 HU 229065B1
Authority
HU
Hungary
Prior art keywords
pharmaceutical composition
lactose
oral use
hydrate
salt
Prior art date
Application number
HU0104762A
Other languages
English (en)
Hungarian (hu)
Inventor
Patrick Bosche
Hans Friedrich Mahler
Claus Weisemann
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7889824&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HU229065(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of HUP0104762A2 publication Critical patent/HUP0104762A2/hu
Publication of HUP0104762A3 publication Critical patent/HUP0104762A3/hu
Publication of HU229065B1 publication Critical patent/HU229065B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HU0104762A 1998-11-10 1999-10-29 Pharmaceutical moxifloxacin compositions HU229065B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19855758 1998-11-10
PCT/EP1999/008230 WO2000027398A1 (de) 1998-11-10 1999-10-29 Pharmazeutische zubereitung von moxifloxacin

Publications (3)

Publication Number Publication Date
HUP0104762A2 HUP0104762A2 (hu) 2002-05-29
HUP0104762A3 HUP0104762A3 (en) 2002-10-28
HU229065B1 true HU229065B1 (en) 2013-07-29

Family

ID=7889824

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0104762A HU229065B1 (en) 1998-11-10 1999-10-29 Pharmaceutical moxifloxacin compositions

Country Status (41)

Country Link
US (1) US6610327B1 (cg-RX-API-DMAC7.html)
EP (1) EP1128831B1 (cg-RX-API-DMAC7.html)
JP (1) JP4809978B2 (cg-RX-API-DMAC7.html)
KR (1) KR100650489B1 (cg-RX-API-DMAC7.html)
CN (1) CN1149993C (cg-RX-API-DMAC7.html)
AR (1) AR021074A1 (cg-RX-API-DMAC7.html)
AT (1) ATE279193T1 (cg-RX-API-DMAC7.html)
AU (1) AU745282B2 (cg-RX-API-DMAC7.html)
BG (1) BG64974B1 (cg-RX-API-DMAC7.html)
BR (2) BRPI9915208B8 (cg-RX-API-DMAC7.html)
CA (1) CA2349161C (cg-RX-API-DMAC7.html)
CO (1) CO5070571A1 (cg-RX-API-DMAC7.html)
CU (1) CU23260B7 (cg-RX-API-DMAC7.html)
CZ (1) CZ292069B6 (cg-RX-API-DMAC7.html)
DE (1) DE59910858D1 (cg-RX-API-DMAC7.html)
DK (1) DK1128831T3 (cg-RX-API-DMAC7.html)
EE (1) EE04418B1 (cg-RX-API-DMAC7.html)
ES (1) ES2229786T3 (cg-RX-API-DMAC7.html)
HK (1) HK1042245B (cg-RX-API-DMAC7.html)
HN (1) HN1999000183A (cg-RX-API-DMAC7.html)
HR (1) HRP20010332B1 (cg-RX-API-DMAC7.html)
HU (1) HU229065B1 (cg-RX-API-DMAC7.html)
ID (1) ID29089A (cg-RX-API-DMAC7.html)
IL (2) IL142642A0 (cg-RX-API-DMAC7.html)
MA (1) MA26757A1 (cg-RX-API-DMAC7.html)
MY (1) MY121114A (cg-RX-API-DMAC7.html)
NO (1) NO319342B1 (cg-RX-API-DMAC7.html)
NZ (1) NZ511554A (cg-RX-API-DMAC7.html)
PE (1) PE20001304A1 (cg-RX-API-DMAC7.html)
PL (1) PL194020B1 (cg-RX-API-DMAC7.html)
PT (1) PT1128831E (cg-RX-API-DMAC7.html)
RU (1) RU2230555C9 (cg-RX-API-DMAC7.html)
SI (1) SI1128831T1 (cg-RX-API-DMAC7.html)
SK (1) SK283936B6 (cg-RX-API-DMAC7.html)
SV (1) SV1999000194A (cg-RX-API-DMAC7.html)
TR (1) TR200101310T2 (cg-RX-API-DMAC7.html)
TW (1) TW580388B (cg-RX-API-DMAC7.html)
UA (1) UA72483C2 (cg-RX-API-DMAC7.html)
UY (1) UY25792A1 (cg-RX-API-DMAC7.html)
WO (1) WO2000027398A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA200103141B (cg-RX-API-DMAC7.html)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19937116A1 (de) * 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin Kochsalzformulierung
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
DE10337191A1 (de) * 2003-08-13 2005-03-17 Bayer Healthcare Ag Neue Verwendung von Chinolon-Antibiotika
EP1663226A1 (en) * 2003-09-03 2006-06-07 Ranbaxy Laboratories Limited Pharmaceutical compositions of moxifloxacin and processes for their preparation
CN1330306C (zh) * 2004-08-11 2007-08-08 深圳市天一时科技开发有限公司 莫西沙星明胶胶囊剂及其制备方法
WO2006015545A1 (fr) * 2004-08-11 2006-02-16 Shenzhen Tys R & D Co., Ltd. Capsule de gelatine de moxifloxacin et procede pour sa preparation
WO2007033515A1 (fr) * 2005-09-21 2007-03-29 Shenzhen Tys R & D Co., Ltd. Formulation orale contenant de la moxifloxacine et son procédé de préparation
WO2007033522A1 (fr) * 2005-09-21 2007-03-29 Shenzhen Tys R & D Co., Ltd. Formulation de gélule contenant de la moxifloxacine et son procédé de préparation
CN100363001C (zh) * 2005-09-21 2008-01-23 深圳市天一时科技开发有限公司 一种莫西沙星胶囊剂及其制备方法
PL2349220T3 (pl) * 2008-10-09 2012-12-31 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Zastosowanie rozpuszczalników organicznych w granulacji na mokro moksyfloksacyny
EP2735307A1 (de) 2008-12-08 2014-05-28 Ratiopharm GmbH Kompaktiertes Moxifloxacin
TR200907227A2 (tr) * 2009-09-18 2011-04-21 Bi̇lgi̇ç Mahmut Çözünürlüğü yüksek stabil mikronize granüller.
CN101890169B (zh) * 2009-11-16 2013-09-11 江苏亚邦强生药业有限公司 莫西沙星口服制剂及其制备方法
WO2011086577A2 (en) * 2010-01-12 2011-07-21 Msn Laboratories Limited Pharmaceutical composition of moxifloxacin and its pharmaceutically acceptable salts
CN102247313A (zh) * 2010-06-11 2011-11-23 北京润德康医药技术有限公司 一种以莫西沙星为活性成分的口服缓释固体制剂
CN102247314A (zh) * 2011-01-12 2011-11-23 北京润德康医药技术有限公司 一种以莫西沙星为活性成分的口服固体制剂
EP2510929A1 (en) * 2011-04-11 2012-10-17 Innocoll Technologies Limited Methods for treating bacterial infection
MX2011004759A (es) 2011-05-04 2012-11-21 Senosiain S A De C V Lab Nuevas formas solidas de antibioticos.
RU2466718C1 (ru) * 2011-10-14 2012-11-20 Закрытое акционерное общество "Брынцалов-А" Фармацевтический препарат моксифлоксацина
WO2013063271A1 (en) * 2011-10-25 2013-05-02 U.S. Phytotherapy, Inc. Artemisinin and berberine compositions and methods of making
EP2770985A4 (en) 2011-10-25 2015-01-21 U S Phytotherapy Inc ARTEMISININE AND BERBERINE COMPOSITIONS AND METHOD FOR THE PRODUCTION THEREOF
US9675582B2 (en) 2011-10-25 2017-06-13 U.S. Phytotherapy, Inc. Alternative ACT with natural botanical active GRAS ingredients for treatment and prevention of the Zika virus
US9358261B2 (en) 2011-10-25 2016-06-07 U.S. Phytotherapy, Inc. Additional artemisinin and berberine compositions and methods of making
WO2013081044A1 (ja) * 2011-11-30 2013-06-06 富山化学工業株式会社 1-シクロプロピル-8-(ジフルオロメトキシ)-7-[(1r)-1-メチル-2,3-ジヒドロ-1h-イソインドール-5-イル]-4-オキソ-1,4-ジヒドロキノリン-3-カルボン酸のメタンスルホン酸塩水和物含有錠剤
BRPI1106900A2 (pt) 2011-12-26 2013-11-05 Ems Sa Composição farmacêutica sólida compreendendo antibótico da familia das quinolonas e processo de sua obtenção
CN102525982A (zh) * 2012-02-21 2012-07-04 天津市汉康医药生物技术有限公司 一种稳定的盐酸莫西沙星药物组合物
CN102600093B (zh) * 2012-04-11 2013-06-05 南京优科生物医药有限公司 一种莫西沙星片剂及其制备方法
FR2992218B1 (fr) 2012-06-22 2015-01-23 Rivopharm Sa Composition pharmaceutique de chlorhydrate de moxifloxacine et procede de preparation
CN103768063B (zh) * 2012-10-19 2016-04-20 深圳信立泰药业股份有限公司 一种盐酸莫西沙星药物组合物及其制备方法
RU2561037C2 (ru) * 2013-02-07 2015-08-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Антибактериальная фармацевтическая композиция и способ ее получения
WO2015093669A1 (ko) * 2013-12-20 2015-06-25 씨제이헬스케어 주식회사 목시플록사신 수성 제형 및 이의 제조방법
RU2558932C1 (ru) * 2014-05-22 2015-08-10 Открытое Акционерное Общество "Татхимфармпрепараты" Фармацевтическая композиция моксифлоксацина и способ ее приготовления

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5286754A (en) 1986-01-21 1994-02-15 Bayer Aktiengesellschaft Pharmaceutical formulations of ciprofloxacin
DE3601566A1 (de) * 1986-01-21 1987-07-23 Bayer Ag Pharmazeutische zubereitungen von ciprofloxacin
WO1989003681A1 (en) * 1987-10-19 1989-05-05 Pfizer Inc. Substituted tetralins, chromans and related compounds in the treatment of asthma
JPH01175936A (ja) * 1987-12-28 1989-07-12 Kyorin Pharmaceut Co Ltd 6.8−ジフルオロ−1−(2−フルオロエチル)−1,4−ジヒドロ−7−(4−メチル−1−ピペラジニル)−4−オキソ−3−キノリンカルボン酸を有効成分とする錠剤
DE3906365A1 (de) * 1988-07-15 1990-01-18 Bayer Ag 7-(1-pyrrolidinyl)-3-chinolon- und -naphthyridoncarbonsaeure-derivate, verfahren sowie substituierte (oxa)diazabicyclooctane und -nonane als zwischenprodukte zu ihrer herstellung, und sie enthaltende antibakterielle mittel und futterzusatzstoffe
EP0449445A3 (en) * 1990-03-27 1993-08-25 Pfizer Inc. Preparation of beta-ketoesters useful in preparing quinolone antibiotics
TW209865B (cg-RX-API-DMAC7.html) * 1992-01-10 1993-07-21 Bayer Ag
DE19546249A1 (de) * 1995-12-12 1997-06-19 Bayer Ag Neue Kristallmodifikation des 1-Cyclopropyl-7-([S,S]-2,8-diazabicyclo[4,3,0]non-8-yl)-6-fluor-1,4-dihydro-8-methoxy-4-oxo-3-chinolincarbonsäure Hydrochlorid (CDCH), Verfahren zu dessen Herstellung und diese enthaltende pharmazeutische Zubereitungen
PA8466701A1 (es) * 1998-01-21 2000-09-29 Pfizer Prod Inc Comprimido de mesilato de trovafloxacino

Also Published As

Publication number Publication date
AU745282B2 (en) 2002-03-21
CU23260B7 (es) 2008-01-24
RU2230555C2 (ru) 2004-06-20
SV1999000194A (es) 2000-10-16
HN1999000183A (es) 1999-11-01
UY25792A1 (es) 2001-08-27
SI1128831T1 (en) 2005-04-30
ATE279193T1 (de) 2004-10-15
PL194020B1 (pl) 2007-04-30
SK283936B6 (sk) 2004-05-04
BG64974B1 (bg) 2006-11-30
PT1128831E (pt) 2005-01-31
BR9915208A (pt) 2001-07-31
DE59910858D1 (de) 2004-11-18
AU1267400A (en) 2000-05-29
JP4809978B2 (ja) 2011-11-09
HUP0104762A2 (hu) 2002-05-29
WO2000027398A1 (de) 2000-05-18
UA72483C2 (en) 2005-03-15
EE04418B1 (et) 2005-02-15
IL142642A0 (en) 2002-03-10
BRPI9915208B1 (pt) 2011-11-01
HK1042245B (zh) 2005-03-11
BRPI9915208A (pt) 2001-07-31
HUP0104762A3 (en) 2002-10-28
IL142642A (en) 2006-10-05
SK6102001A3 (en) 2001-12-03
ES2229786T3 (es) 2005-04-16
KR20010089424A (ko) 2001-10-06
NO20012248L (no) 2001-06-06
NO319342B1 (no) 2005-07-18
BRPI9915208B8 (pt) 2021-07-06
HRP20010332B1 (hr) 2011-01-31
KR100650489B1 (ko) 2006-11-28
CA2349161A1 (en) 2000-05-18
CZ20011652A3 (cs) 2001-08-15
US6610327B1 (en) 2003-08-26
RU2230555C9 (ru) 2006-02-27
MY121114A (en) 2005-12-30
HK1042245A1 (en) 2002-08-09
ZA200103141B (en) 2002-05-07
JP2002529415A (ja) 2002-09-10
BG105459A (en) 2001-12-29
NO20012248D0 (no) 2001-05-07
PE20001304A1 (es) 2000-12-30
CN1149993C (zh) 2004-05-19
TR200101310T2 (tr) 2001-10-22
HRP20010332A2 (en) 2002-06-30
MA26757A1 (fr) 2004-12-20
AR021074A1 (es) 2002-06-12
CN1325306A (zh) 2001-12-05
EE200100259A (et) 2002-12-16
PL348112A1 (en) 2002-05-06
NZ511554A (en) 2003-07-25
CO5070571A1 (es) 2001-08-28
DK1128831T3 (da) 2005-01-17
EP1128831A1 (de) 2001-09-05
CZ292069B6 (cs) 2003-07-16
ID29089A (id) 2001-07-26
TW580388B (en) 2004-03-21
CA2349161C (en) 2008-01-29
EP1128831B1 (de) 2004-10-13

Similar Documents

Publication Publication Date Title
KR100650489B1 (ko) 목시플록사신 제약 제제
JP4868695B2 (ja) 崩壊性が良好な経口製剤
US20030228360A1 (en) Combination immediate release controlled release levodopa/carbidopa dosage forms
HU229152B1 (en) Multiparticulate tablets with quick disintegration
EP1507518B1 (en) Combination immediate release controlled release levodopa/carbidopa dosage forms
CZ268197A3 (cs) Farmaceutická kompozice stabilizovaná zásaditým činidlem
WO2009101940A1 (ja) 溶出性の改善された錠剤
WO2008053297A2 (en) Pharmaceutical compositions comprising entacapone, levodopa, and carbidopa
EP2242483B1 (en) Raloxifene composition
CA2209868C (en) Pharmaceutical compositions comprising cefuroxime axetil
JP2001522882A (ja) ザファルカストを含有する医薬品組成物
HU226528B1 (en) Cyclophosphamide coated tablets
EP2095815B1 (en) Pharmaceutical formulations containing clopidogrel
AU2003267216A1 (en) Mannitol formulation for integrin receptor antagonist
WO2008053295A2 (en) Pharmaceutical compositions of benzoquinolizine-2-carboxylic acid
HK1046234A1 (en) Ciprofloxacin containing pharmaceutical composition and process for the preparation thereof
HU225472B1 (en) High-content famciclovir pharmaceutical tablets
TR2021011580A2 (tr) Geli̇şti̇ri̇lmi̇ş çözünme hizina sahi̇p li̇nagli̇pti̇n i̇çeren fi̇lm kapli tablet formülasyonlari
HRP20020153A2 (en) Ciprofloxacin containing pharmaceutical composition and process for the preparation thereof
WO2011157730A1 (en) Process for the preparation of controlled release tablet

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, DE

Free format text: FORMER OWNER(S): BAYER AG., DE; BAYER HEALTHCARE AG., DE

GB9A Succession in title

Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE

Free format text: FORMER OWNER(S): BAYER AG., DE; BAYER HEALTHCARE AG., DE; BAYER PHARMA AKTIENGESELLSCHAFT, DE; BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, DE

HC9A Change of name, address

Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE

Free format text: FORMER OWNER(S): BAYER AG., DE; BAYER HEALTHCARE AG., DE; BAYER PHARMA AKTIENGESELLSCHAFT, DE; BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, DE